【2017年整理】关于红斑狼疮的一些资料更新.docVIP

PAGE PAGE 74 红斑性狼疮 （Systemic Lupus Erythematosus (SLE)，又称全身性红斑狼疮或系统性红斑狼疮 HYPERLINK /wiki/%E7%B4%85%E6%96%91%E7%8B%BC%E7%98%A1 \l cite_note-0#cite_note-0 [1]）为一种慢性的 HYPERLINK /wiki/%E8%87%AA%E4%BD%93%E5%85%8D%E7%96%AB \o 自体免疫 自体免疫疾病。和其他自体免疫疾病一样，免疫系统攻击自身细胞和组织，导致发炎和组织损害。红斑性狼疮可能影响各种器官，包括心脏、关节、皮肤、肺、血管、肝、肾脏，以及神经系统。SLE的自然病程多表现为病情的加重与缓解交替，通常无法预知何时发病。任何年龄的人都可能得到红斑性狼疮，但它通常发生于年轻 HYPERLINK /wiki/%E5%A5%B3%E6%80%A7 \o 女性 女性，有90%的患者是女性。红斑性狼疮目前无法治愈，但它的症状是可以治疗的，以使用类固醇和免疫抑制剂为主。 Lupus语出拉丁文，原意是“狼”的意思，因为SLE患者长的红斑像被狼咬过的伤口，Erythematosus是形容其典型症状──鼻梁及两侧有对称的红斑，状似蝴蝶。 造成红斑性狼疮的发病机理，是因患者体内产生许多对抗自身细胞物质的 HYPERLINK /wiki/%E6%8A%97%E4%BD%93 \o 抗体 抗体，包括抗核抗体、抗双股去氧核糖核酸抗体、抗萃取核抗原抗体等多种。 关于新药BENLYSTA（贝利单抗）（ HYPERLINK /BENLYSTA.html /BENLYSTA.html） BENLYSTA is an investigational human monoclonal antibody drug. It is the first in a new class of drugs called BLyS-specific inhibitors that recognize and inhibit the biological activity of B-lymphocyte stimulator, or BLyS, which was discovered by HGS in 1996. We and GlaxoSmithKline (GSK) are developing BENLYSTA under a co-development and commercialization agreement entered into in 2006. In lupus, rheumatoid arthritis and certain other autoimmune diseases, elevated levels of BLyS are believed to contribute to the production of autoantibodies – antibodies that attack and destroy the body’s own healthy tissues. BENLYSTA has successfully met its primary endpoint in two pivotal Phase 3 trials in seropositive patients with systemic lupus erythematosus (SLE). In June 2010, HGS and GSK submitted regulatory applications seeking approval to market BENLYSTA in the United States and Europe. The FDA has granted BENLYSTA a priority review designation with a Prescription Drug User Fee Act (PDUFA) target date of December 9, 2010 – so it is possible that BENLYSTA could receive regulatory approval in the United States before the end of 2010. 谷歌翻译： BENLYSTA是研究人类单克隆抗体药物。这是第一次在一个所谓的BLYS特定抑制剂的药物，能够识别并抑制B淋巴细胞刺激，或BLYS，这是由HGS在1996年发现的生物活性的新的类。我们和葛兰素史克（GSK）是根据2006年订立的协议共同开发和商业化发展BEN